•  
  •  
  •  
  •  

2026-07-21 18:06:48

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Nureca Limited Turns Around in Q1 FY27: Posts Profit Before Tax of INR 44.33 Million as Revenues Surge
  • Anthem Biosciences Limited Reports Q1 FY27 Net Profit of ₹1,199 Million on Revenues of ₹4,182 Million
  • ANVISA Approval for CuraTeQ Biologics' Biosimilars Manufacturing Facility
  • JSW Infrastructure Posts 18% Revenue Growth to ₹1,445 Crore in Q1 FY27; Operating EBITDA Reaches ₹674 Crore
  • TVS Holdings Reports Net Profit Jump of 73.8% to ₹1,173.58 Crore for Q1 FY27

Keywords Selected:  OneSourceSpecialtyPharma

Stock Report

  • OneSource Specialty Pharma and Formycon AG announce Strategic Manufacturing Partnership for Biosimilars
  • Completion of US-FDA Inspection at Sterile Product Division facility at Bengaluru
  • OneSource Specialty Pharma Ltd consolidated Q4 FY2026 profit at Rs. 4.59 crores
  • OneSource Supports Second Generic Semaglutide Approval in Canada
  • OneSource's Partner Dr. Reddy's Laboratories receives Health Canada Approval for Generic Semaglutide Injection
  • OneSource Specialty Pharma Ltd receives EU GMP Certificate for Sterile Product Division
  • Orbicular's Partner secures tentative U.S. ANDA approval for a generic version of Semaglutide Injection, supported by OneSource as CDMO partner
  • OneSource Specialty Pharma Ltd receives renewal of EU-GMP certification for Unit 2
  • OneSource-Hikma partnership secures approval to commercialise generic version of Ozempic® in Saudi Arabia
  • OneSource and Xbrane Biopharma Announce Biosimilars Manufacturing Partnership for the Global Markets
  • OneSource's flagship drug-device combination facility in Bangalore maintains its USFDA compliance status
  • OneSource Specialty Pharma Ltd reports consolidated Q4FY25 PAT of Rs. 98.50 crores
  • OneSource Specialty Pharma Ltd secures Brazilian GMP approval for its flagship facility Unit 2
  • OneSource Specialty Pharma Ltd updates on cGMP inspection by USFDA
  • OneSource receives equity commitments of INR 8,010 mn from marquee investors at a pre-money equity valuation of USD 1.65 bn
  • Strides announces approval from Equity Shareholders and Secured Creditors for creation of OneSource - India's first Specialty Pharma CDMO

Latest Post

  • Nureca Limited Turns Around in Q1 FY27: Posts Profit Before Tax of INR 44.33 Million as Revenues Surge
  • Anthem Biosciences Limited Reports Q1 FY27 Net Profit of ₹1,199 Million on Revenues of ₹4,182 Million
  • ANVISA Approval for CuraTeQ Biologics' Biosimilars Manufacturing Facility
  • JSW Infrastructure Posts 18% Revenue Growth to ₹1,445 Crore in Q1 FY27; Operating EBITDA Reaches ₹674 Crore
  • TVS Holdings Reports Net Profit Jump of 73.8% to ₹1,173.58 Crore for Q1 FY27


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025